- Home
- GTY vs IRON Comparison
GTY vs IRON Comparison
Compare GTY & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTY
- IRON
- Stock Information
- Founded
- GTY 1955
- IRON 2017
- Country
- GTY United States
- IRON United States
- Employees
- GTY N/A
- IRON N/A
- Industry
- GTY Real Estate
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- GTY Finance
- IRON Health Care
- Exchange
- GTY Nasdaq
- IRON Nasdaq
- Market Cap
- GTY 1.6B
- IRON 1.4B
- IPO Year
- GTY N/A
- IRON N/A
- Fundamental
- Price
- GTY $29.08
- IRON $47.73
- Analyst Decision
- GTY Buy
- IRON Strong Buy
- Analyst Count
- GTY 6
- IRON 9
- Target Price
- GTY $32.50
- IRON $93.89
- AVG Volume (30 Days)
- GTY 316.4K
- IRON 356.0K
- Earning Date
- GTY 07-23-2025
- IRON 05-07-2025
- Dividend Yield
- GTY 6.46%
- IRON N/A
- EPS Growth
- GTY 2.68
- IRON N/A
- EPS
- GTY 1.20
- IRON N/A
- Revenue
- GTY $206,751,000.00
- IRON N/A
- Revenue This Year
- GTY $5.31
- IRON N/A
- Revenue Next Year
- GTY $7.19
- IRON N/A
- P/E Ratio
- GTY $24.25
- IRON N/A
- Revenue Growth
- GTY 7.80
- IRON N/A
- 52 Week Low
- GTY $25.70
- IRON $30.82
- 52 Week High
- GTY $33.85
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- GTY 54.57
- IRON 53.17
- Support Level
- GTY $28.11
- IRON $44.47
- Resistance Level
- GTY $29.39
- IRON $47.36
- Average True Range (ATR)
- GTY 0.48
- IRON 2.22
- MACD
- GTY 0.11
- IRON -0.06
- Stochastic Oscillator
- GTY 81.14
- IRON 55.44
About GTY Getty Realty Corporation
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.